



Press Release

Granules India's two facilities located in Vizag (Andhra Pradesh) and Jeedimetla (Telangana) completed U.S. FDA inspection.

Hyderabad, December 21, 2015: Granules India Ltd., announced today that two of its facilities located in Vizag (Andhra Pradesh) and Jeedimetla (Telangana) have completed USFDA inspection. There are no observations for Vizag facility and three (3) observations for Jeedimetla facility. The Company will respond to the observations in fifteen (15) business days.

About Granules India Ltd.

(BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

Contacts:

Sumanta Bajpayee
Granules India Ltd.
040-30663572
sumanta.bajpayee@granulesindia.com

Govindan JM
Genesis Burson-Marsteller
+91 9703700884
Govindan.JM@bm.com